ATE334696T1 - Abin zum schutz gegen hepatitis - Google Patents
Abin zum schutz gegen hepatitisInfo
- Publication number
- ATE334696T1 ATE334696T1 AT02751083T AT02751083T ATE334696T1 AT E334696 T1 ATE334696 T1 AT E334696T1 AT 02751083 T AT02751083 T AT 02751083T AT 02751083 T AT02751083 T AT 02751083T AT E334696 T1 ATE334696 T1 AT E334696T1
- Authority
- AT
- Austria
- Prior art keywords
- abin
- protect against
- against hepatitis
- relates
- overexpressing
- Prior art date
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract 1
- 206010019663 Hepatic failure Diseases 0.000 abstract 1
- 206010019799 Hepatitis viral Diseases 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 231100000225 lethality Toxicity 0.000 abstract 1
- 208000007903 liver failure Diseases 0.000 abstract 1
- 231100000835 liver failure Toxicity 0.000 abstract 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 201000001862 viral hepatitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Botany (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01202414 | 2001-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334696T1 true ATE334696T1 (de) | 2006-08-15 |
Family
ID=8180525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02751083T ATE334696T1 (de) | 2001-06-22 | 2002-06-20 | Abin zum schutz gegen hepatitis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7094756B2 (https=) |
| EP (1) | EP1397154B1 (https=) |
| JP (1) | JP4252446B2 (https=) |
| AT (1) | ATE334696T1 (https=) |
| AU (1) | AU2002350412B2 (https=) |
| CA (1) | CA2447249A1 (https=) |
| DE (1) | DE60213596T2 (https=) |
| ES (1) | ES2269736T3 (https=) |
| WO (1) | WO2003000280A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE334696T1 (de) | 2001-06-22 | 2006-08-15 | Vlaams Interuniv Inst Biotech | Abin zum schutz gegen hepatitis |
| WO2004101745A2 (en) * | 2003-05-08 | 2004-11-25 | Beth Israel Deaconess Medical Center, Inc. | NOVEL REGULATORY MECHANISMS OF NF-kappaB |
| BRPI0414714A (pt) | 2003-09-24 | 2006-11-21 | Pasteur Institut | polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição |
| WO2006029981A1 (en) * | 2004-09-13 | 2006-03-23 | Vib Vzw | Abin-mediated protection against lung inflammatory disease |
| EP1871406A1 (en) * | 2005-04-14 | 2008-01-02 | VIB vzw | Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) * | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) * | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) * | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) * | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) * | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| UA71889C2 (uk) | 1996-04-02 | 2005-01-17 | Йєда Рісерч Енд Дівелопмент Ко. Лтд. | Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування |
| ES2251831T3 (es) * | 1998-05-06 | 2006-05-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Inhibidores de la activacion de nf-kb. |
| ATE334696T1 (de) | 2001-06-22 | 2006-08-15 | Vlaams Interuniv Inst Biotech | Abin zum schutz gegen hepatitis |
-
2002
- 2002-06-20 AT AT02751083T patent/ATE334696T1/de not_active IP Right Cessation
- 2002-06-20 EP EP02751083A patent/EP1397154B1/en not_active Expired - Lifetime
- 2002-06-20 ES ES02751083T patent/ES2269736T3/es not_active Expired - Lifetime
- 2002-06-20 CA CA002447249A patent/CA2447249A1/en not_active Abandoned
- 2002-06-20 WO PCT/EP2002/007154 patent/WO2003000280A2/en not_active Ceased
- 2002-06-20 AU AU2002350412A patent/AU2002350412B2/en not_active Ceased
- 2002-06-20 DE DE60213596T patent/DE60213596T2/de not_active Expired - Lifetime
- 2002-06-20 JP JP2003506924A patent/JP4252446B2/ja not_active Expired - Fee Related
-
2003
- 2003-12-19 US US10/741,923 patent/US7094756B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60213596T2 (de) | 2007-09-13 |
| EP1397154B1 (en) | 2006-08-02 |
| CA2447249A1 (en) | 2003-01-03 |
| AU2002350412B2 (en) | 2006-06-15 |
| US20040136978A1 (en) | 2004-07-15 |
| US7094756B2 (en) | 2006-08-22 |
| EP1397154A2 (en) | 2004-03-17 |
| WO2003000280A2 (en) | 2003-01-03 |
| JP2004536827A (ja) | 2004-12-09 |
| ES2269736T3 (es) | 2007-04-01 |
| DE60213596D1 (de) | 2006-09-14 |
| WO2003000280A3 (en) | 2003-03-20 |
| JP4252446B2 (ja) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20120356A (es) | Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas | |
| ECSP045429A (es) | Combinacion de compuestos organicos | |
| PT1268519E (pt) | Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c | |
| BR0305426A (pt) | Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos | |
| CL2004001174A1 (es) | Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia | |
| WO2004110351A3 (en) | Heterocyclic compounds for treating hepatitis c virus | |
| BRPI0416902A (pt) | inibidores de ns3/ns4a serina protease do vìrus da hepatite c | |
| NO20081846L (no) | Bifenylderivater og deres anvendelse ved behandling av hepatitt C | |
| MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
| NO20073105L (no) | Pyridazinonforbindelser | |
| BRPI0508095A (pt) | compostos como inibidores de ns3 serina protease do vìrus da hepatite c | |
| BR0305259A (pt) | Inibidores de hcv ns5b polimerase | |
| BR0306931A (pt) | Peptìdeos como inibidores de protease serina-ns3 do vìrus da hepatite c | |
| IS7530A (is) | Lifrarbólgu C-veirutálmar | |
| BRPI0407587A (pt) | inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam | |
| SG159542A1 (en) | Compositions against sars-coronavirus and uses thereof | |
| BR0208142A (pt) | Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona | |
| WO2007092645A3 (en) | Novel hcv inhibitor combinations and methods | |
| WO2007084435A8 (en) | Methods for treating hepatitis c | |
| WO2008073982A3 (en) | 5,6-dihydro-1h-pyridin-2-one compounds | |
| ATE555794T1 (de) | Heilmittel gegen hepatitis | |
| ATE334696T1 (de) | Abin zum schutz gegen hepatitis | |
| WO2004043404A3 (en) | Process for designing inhibitors of influenza virus non-structural protein 1 | |
| DE60305884D1 (de) | Igg3 immunogloblin als schutzsmarker gegen viren infektiösen krankheiten und seine verwendungen | |
| WO2007059221A3 (en) | Hepatitis c virus variants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1397154 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |